Pharmaceutical inhibition of dipeptidyl peptidase IV (DPP-IV) is a recently explored strategy aimed to benefit patients with type-II diabetes to regulate plasma glucose levels. X-ray crystallographic studies of DPP-IV in complex with inhibitors aided drug candidate discovery through structure-based evaluation and design. This presentation will highlight contributions of structural biology to these efforts at Abbott Laboratories.